

SARS-CoV-2 trimeric soluble full-length Spike protein, Beta variant, S protein Cat#: orb864237 (CoA)

Name: Recombinant SARS-CoV-2 Spike protein, Beta Variant of Concern, B.1.351 variant

Full-length soluble with foldon trimerization motif, mutated Furin recognition site and 4 stabilising mutations (A892P, A942P, K986P and V987P), based on/modified from Amanat *et al*, 2020 and Hsieh *et al*, 2020.

Synonyms:Spike glycoprotein, S protein.Species:Severe Acute Respiratory Syndrome Coronavirus 2Source:HEK293Amino Acids:16-1211Tag:8xHis at the C terminus.Predicted Molecular Weight:137 kDaProtein ID:PODTC2

Sequence:

VNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSN IIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQ GNFKNLREFVFKNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPR TFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRIS NCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTG**N**IADYNYKLPDDFTGCVIAWNSNNLDS KVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGV**K**GFNCYFPLQSYGFQPT**Y**GVGYQPYRVVVLSFELLHAPATVCGP KKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLY Q**G**VNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR**GAG**SVASQSIIAYT MSLG**V**ENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEV FAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDE MIAQYTSALLAGTITSGWTFGAG**P**ALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSST**P**SALGKLQDV VNQNAQALNTLVKQLSSNFGAISSVLNDILSRLD**P**EAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQ SKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTD NTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELG KYEQYIK**SGGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSHHHHHHHH**



Product specifications

Estimated Molecular Weight, SDS-PAGE: ≈190 kDa Grade & Purity: >90% as estimated by SDS-PAGE stained with Instant Blue Stain (Expedeon).



Endotoxins: Less than 0.1 ng/ μ g (1 IEU/ μ g), as measured by LAL method. **Amounts and concentration:** 2x 700 μ l of 0.2mg/ml by A280 absorbance = 280 μ g total protein

Formulation: PBS 20% Glycerol

Batch/Lot number: DB5148



Shipping

Product is shipped either on dry or wet ice or frozen gel packs. Upon receipt, store at -20°C to -70°C.

Product application and Storage

Storage: The protein should be stored at -20°C to -70°C preferably in small aliquots to avoid repeated freeze-thaw cycles.

Stability: At least 12 months at -20°C to -70°C and at least 1 month at 2°C to 8°C.

Application Note: For research purposes only. Not for use in humans.

Functional data

 Protein was immobilised on 96-well plates as a capture antigen. Human serum samples from a serological verification panel containing anti-SARS-CoV-2 antibodies from National Institute of Biological Standards and Controls, NIBSC (20/B770) were added to the plate for incubation and subsequent washing. Secondary human anti-IgG, HRP-conjugated, were added for detection in a sandwich ELISA format. The final colorimetric reaction occurs upon addition of TMB substrate which is quenched by the addition of acid solution.



NIBSC references (20/268):

- N negative
- L low positive
- M medium positive
- H high positive
- C calibrant

Biorbyt Ltd. 5 Orwell Furlong, Cowley Road,Cambridge, Cambridgeshire CB4 0WY, United Kingdom Email: info@biorbyt.com | Phone: +44 (0)1223 859 353 | Fax: +44(0)1223 280 240

Biorbyt LLC Suite 103, 369 Pine Street, San Francisco California 94104, United States Email: info@biorbyt.com | Phone: +1 (415)-906-5211 | Fax: +1 (415) 651 8558

2. Binding curve of anti-Cov-19&SARS S glycoprotein antibody IgG CR3022 (Absolute Antibody) to the trimeric Spike B.1.351, beta variant:



Background Information

The first reports of atypical pneumonia in China were announced at the very end of 2019, in the city of Wuhan, Hubei province. Its cause was identified in January 2020 as a novel β -CoV (1), named SARS-CoV-2, which started spreading very quickly causing a global pandemic COVID-19.

Spike protein attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein (2, 3). The protein forms a trimer *in vivo* mediating receptor binding and membrane fusion (4). It has been demonstrated by Florian Krammer's group that certain mutations and the inclusion of trimerization motif can stabilize recombinant Spike protein (5, 6).

The original Wuhan strain of the virus has become quickly replaced by its more transmissible variant, mainly determined by a single amino acid point mutation D614G (7).

The B.1.351 variant is a strain of the coronavirus with 9 distinctive mutations (in addition to the D614G) in the virus's spike protein, the structure that allows the virus to bind to and infect human cells (8).



References:

- 1. Zhu N., Zhang D., Wang W., et al. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med.*, 2020;382:727–733.
- 2. Hoffmann M., Kleine-Weber H., Schroeder S., *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*, 2020;181(2):271-280.
- 3. Wrapp D., Wang N., Corbett KS., *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*, 2020;367(6483):1260-1263.
- 4. Yin HS., Wen X., Paterson RG., Lamb RA., Jardetzky TS. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. *Nature*, 2006;439(7072):38-44.
- 5. Amanat, F., Stadlbauer, D., Strohmeier, S., *et al.* A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med.*, 2020;26:1033–1036.
- 6. Stadlbauer, D., Amanat, F., Chromikova, V., *et al.* SARS-CoV-2 seroconversion in humans: A detailed protocol for a serological assay, antigen production, and test setup. *Current Protocols in Microbiology*, 2020;57, e100.
- 7. Korber, B., Fischer, W., Gnanakaran, S., *et al.* Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. *Cell*, 2020;182:1-16.
- 8. Tegally, H., Wilkinson, E., Giovanetti, M., *et al.* Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple Spike mutations in South Africa. *MedRxiv*, 21.12.2020;182:1-16.